uniQure to Announce 2025 Financial Results
Rhea-AI Summary
uniQure (NASDAQ: QURE) will report fourth-quarter and full-year 2025 financial results before market open on Monday, March 2, 2026. Management will host a live conference call at 8:00 a.m. ET the same day.
The event will be webcast via the company’s Events & Presentations page and a replay will be archived for 90 days. Analysts may join the live Q&A by phone using conference ID 4607289; attendees are asked to dial in 15 minutes early.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers in Biotechnology show mixed moves: some names like EYPT, ABUS, and OCS have positive or modestly positive changes, while TSHA and UPB are negative. Momentum scanner data flags only EYPT moving lower, supporting a stock-specific setup around this earnings-date notice rather than a broad sector trend.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings date notice | Neutral | +5.6% | Set timing for Q3 2025 results and investor conference call. |
The single prior earnings-date announcement over the last six months was followed by a positive one-day move of 5.56%.
Over the past several months, uniQure has combined clinical progress with active regulatory dialogue and capital activity. A prior earnings-date announcement on Nov 06, 2025 preceded Q3 2025 results and coincided with a 5.56% one-day gain. Since then, the company has reported mixed regulatory signals for AMT-130 and raised substantial capital, while advancing programs like AMT-191. Today’s notice schedules the release of Q4 and full-year 2025 results, continuing its pattern of pre-announcing earnings calls.
Historical Comparison
Past earnings-date news for QURE saw an average move of 5.56%. This announcement is another scheduling update ahead of financial results, consistent with prior communication patterns.
Earnings-date communications moved from announcing Q3 2025 timing to now scheduling Q4 and full-year 2025 results, indicating continued regular financial disclosure practices.
Market Pulse Summary
This announcement schedules uniQure’s Q4 and full-year 2025 results for March 2, 2026, with an earnings call at 8:00 a.m. ET. Historically, the last earnings-date notice preceded a 5.56% gain, suggesting these updates can matter at the margin. Investors may watch for how upcoming results intersect with recent regulatory feedback on AMT-130, prior capital raises, and notable institutional ownership changes disclosed in recent Schedule 13G and 13G/A filings.
AI-generated analysis. Not financial advice.
~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 4607289. If you are joining the conference call, please join 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Contacts:
| FOR INVESTORS: | FOR MEDIA: |
| Chiara Russo | Tom Malone |
| Direct: 781-491-4371 | Direct: 339-970-7558 |
| Mobile: 617-306-9137 | Mobile:339-223-8541 |
| c.russo@uniQure.com | t.malone@uniQure.com |
FAQ
When will uniQure (QURE) report full-year 2025 results and hold the earnings call?
How can investors and analysts access the uniQure (QURE) March 2, 2026 earnings webcast?
What are the dial-in details for analysts who want to join the uniQure (QURE) March 2, 2026 conference call?
Will a replay of the uniQure (QURE) March 2, 2026 earnings call be available and for how long?
What topics will uniQure (QURE) management cover on the March 2, 2026 earnings call?
